Dr. Jacques P. Tremblay from University of Laval, Quebec joins the speaker panel for the 2nd Annual Genome Editing & Engineering Conference
MarketsandMarkets Conferences are excited to introduce the 2nd Annual Genome Editing & Engineering Conference (6th - 7th February 2017 in San Diego).The conference brings together the key industry leaders and researchers to address the concepts, challenges & applications of the genome editing tools like CRISPR/Cas9, TALENs.
- (1888PressRelease) October 01, 2016 - MarketsandMarkets Conferences, who are organizing the 2nd Annual Genome Editing & Engineering Conference, confirmed today that Dr. Jacques P. Tremblay, Full Professor, Department of Molecular Medicine, University of Laval, Quebec, Canada has joined the speaker panel for the conference. The event co - located with the 2nd Annual Biomarker Conference and 2nd annual NGS Data Analysis and Informatics Conference is scheduled for 6th - 7th February 2017 in San Diego, CA. The conference will gather key industry leaders and researchers from academia, pharma and bio - pharma organizations to address the concepts, challenges and applications of genome editing tools like CRISPR/Cas9, TALENs.
The marketing team at MarketsandMarkets Conferences did a small pre - event interview with Dr. Tremblay, talking about emerging research areas in genome editing and engineering. Dr. Tremblay said, "Cancer is due to multiple genetic and epigenetic alterations that drive abnormal cell proliferation and permit resistance to chemotherapy. CRISPR/Cas9 permits to correct or ablate such mutations and thus may eventually permit to treat cancer". He further added, "Because of its high efficiency and accuracy, CRISPR/Cas9 genome editing technique is already used to explore in cancer therapies. Several studies used CRISPR/Cas9 to target cancer cell mutations in cellular and animal cancer models. This may permit to demonstrate their therapeutic potential. CRISPR/Cas9 may also be used to fight oncogenic infections, explore anticancer drugs, and engineer immune cells and oncolytic viruses for immunotherapy of cancer. However, there is still a lot of research to be done before the first clinical application.
Dr. Tremblay will be presenting at the conference on use of CRISPR/Cas9 system to correct mutations responsible for Duchenne Muscular Dystrophy and Friedreich ataxia. Joining Dr. Tremblay on the panel will be experts representing organizations such as University of Utah School of Medicine, Massachusetts Institute of Technology, J. Craig Venter Institute, University of Nebraska Medical Center, University of California, University of Washington, University of Southern California, University of Rochester, National Institutes of Health, University of Texas, University of Minnesota, Hiroshima University and Wellcome Trust Sanger Institute.
Special emphasis will be given on CRISPR system - addressing the concept, technology and challenges like integration of genome, off-target effects, and delivery systems. Taking these elements into consideration some of the key topics of discussion at the conference will be RNA guided nuclease for genome modifications, different gene delivery systems, CRISPR as a molecular tool for programmable gene expression and gene therapy, human gene therapy using Zebrafish model, gene knock in and genomic screening using TALEN and CRISPR, CRISPR biomedical research applications, RNAi based screening technologies, genome editing for disease modeling and NgAgo as the latest tool for genome editing.
The conference will be an excellent opportunity to network, share expertise with industry peers and stay updated about the latest advancements in genomics and gene engineering. The conference is supported by California Life Sciences Association (CLSA), ArizonaBio, BioUtah, Colorado BioScience Association, Georgia Bio, Northwest Association for Biomedical Research (NWABR) and The Bioscience Association of Maine (BAM).
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam